The latest updates from AFAR.

Board Member in the News: James Kirkland on Senolytic Drugs in CNN and JAGS

Sep 6

Board Member in the News: James Kirkland on Senolytic Drugs in CNN and JAGS View MoreBACK

On September 5, 2017, featured research by AFAR President-elect and 2012 Glenn/AFAR Breakthroughs in Gerontology Award recipient James Kirkland, MD, PhD, originally published in the Journal of the American Geriatrics Society (JAGS).

The article, New class of drugs targets aging to help keep you healthy, describes how Dr. Kirkland and fellow researchers developed the first drugs to effectively remove harmful senescent cells while leaving normal cells unaffected.

The study, The Clinical Potential of Senolytic Drugs, found that these drugs could also potentially alleviate frailty in older adults and treat conditions associated with chemotherapy or radiotherapy. Dr. Kirkland explains: “In mice, if you treat one leg with enough radiation, after three months, the mouse has trouble walking. If you give a single dose of these drugs, they're able to walk quite well, and that persists for two years. These drugs could mitigate the effects of therapeutic radiation."

Read the full CNN article here. The research is also spotlighted in an article on

The full JAGS study is only accessible with a subscription, but an abstract is available here.

James Kirkland, MD, PhD, is the Director of the Robert and Arlene Kogod Center on Aging at the Mayo Clinic.

For more information on senescent cells, we encourage you to explore our expert-edited Infoaging Guide to Cellular Senescence here.